mavacoxib

Mavacoxib is a long-acting non-steroidal anti-inflammatory drug (NSAID) of the coxib class, specifically developed for veterinary use in dogs. It functions as a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme, which is responsible for the synthesis of pro-inflammatory prostaglandins. By selectively targeting COX-2 while sparing COX-1 at therapeutic concentrations, mavacoxib effectively reduces pain and inflammation associated with degenerative joint disease (osteoarthritis) with a reduced risk of gastrointestinal side effects compared to non-selective NSAIDs. A distinguishing feature of mavacoxib is its exceptionally long elimination half-life in dogs, which allows for a convenient once-monthly dosing regimen following an initial loading period. Xiamen Origin Biotech is developing this small molecule for the veterinary market to address chronic pain and inflammation.

Brand names

Trocoxil

Other names

mavacoxib4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide